Skip to content

Public FDA record

Z-2036-2023: Vanta with AdaptiveStim Implantable Neurostimulator, Model 977006; spinal chord stimulation

Recall record Z-2036-2023 for Medtronic Neuromodulation. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-2036-2023
Company in FDA record
Medtronic Neuromodulation
FDA classification date
Jun 29, 2023
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class II

Reason stated in the source

A cardioversion procedure may damage the electronics in the Vanta INS device, making the INS unresponsive and non-functional. As of April 19, 2023, Medtronic has received a total of two complaints concerning this issue from patients implanted with a Vanta INS, both of which have resulted in explant procedures.

Source facts

Action
Medtronic issued an Urgent Medical Device Correction notice to impacted physicians on 06/06/2023 by letter. The notice explained the problem and the hazard associated with the use of the device during cardioversion procedures. It also provided the following information: Required Actions: " Please communicate to your patients the above Instruction for Prescribers (IFP) and Patient Therapy Guide (PTG) updates regarding programming considerations for cardioversion procedures with patients implanted with Vanta INS devices. " If a patient will be undergoing a cardioversion procedure (e.g., nonemergent scenario) refer to the recommended neurostimulator settings and programming considerations in the Information for Prescribers (IFP) manual which include not turning off your patient s Vanta INS device and reprogramming the settings. " After a cardioversion procedure, confirm that the neurostimulator is functioning and programmed as intended. Contact Medtronic if you have any questions. " For patients who are considering a new or replacement implant, and who have concomitant conditions such that they may require future cardioversion, please talk to these patients about the relative benefits and risks associated with proceeding with a Vanta INS device. " Share this notice with all those who need to be aware of this issue within your organization or to any organization where the potentially affected devices have been transferred and maintain a copy of this notice in your records. " Please complete and return the Customer Confirmation Form enclosed with this letter, acknowledging that you have received this information. Notification will be to the patient level.
Initiated
2023-06-06
Root cause
Device Design
Distribution
Worldwide distribution.
Recall number
Z-2036-2023
Recall status
Open, Classified
CDRH record ID
200873
FDA classified
2023-06-29
Recall event number
92413

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗